IDiyas

For the Inventor, By the Inventor

Basel, Switzerland

Marc Montavon

USPTO Granted Patents = 16

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 56(Granted Patents)


Company Filing History:

goldMedal16 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents

Years Active: 1976-1990

Loading Chart...
16 patents (USPTO):Explore Patents
1. 4908363 - Imidazole derivatives (1990-03-13),
2. 4831151 - Antimicrobial imidazolium derivatives (1989-05-16),
3. 4711889 - Schistosomicidal acridanone hydrazones (1987-12-08),
4. 4544659 - Schistosomicidal acridanone hydrazones (1985-10-01),
5. 4409387 - Cephalosporin derivatives (1983-10-11),
6. 4349672 - Cephalosporin derivatives (1982-09-14),
7. 4348518 - Cephalosporins (1982-09-07),
8. 4327210 - Thiazolylacelamide cephalosporins (1982-04-27),
9. 4292428 - Cephalosporin derivatives (1981-09-29),
10. 4178443 - Derivatives of 7 [-substituted oxyimins acetamido] cephalosporins (1979-12-11),
11. 4146620 - Antibacterial compositions (1979-03-27),
12. 4091211 - Cephalosporins (1978-05-23),
13. 4089950 - Antibacterial compositions (1978-05-16),
14. 4039667 - Antibacterial compositions (1977-08-02),
15. 3996357 - Antibacterial compositions (1976-12-07),

Title: Innovations by Inventor Marc Montavon: A Deep Dive into His Contributions

Introduction

Marc Montavon, an innovative inventor based in Basel, Switzerland, has made significant strides in the field of pharmaceuticals. With a remarkable total of 16 patents to his name, he has played a crucial role in developing new compounds aimed at addressing various health issues.

Latest Patents

Among his latest contributions are groundbreaking patents for imidazole derivatives. These compounds possess valuable pharmacodynamic properties, particularly inflammation-inhibiting and edema-inhibiting characteristics. They serve a critical role in the management and prevention of illnesses related to inflammation and edema. Additionally, he has developed antimicrobial imidazolium derivatives that exhibit pharmacological properties, including antibacterial, antimycotic, protozoacidal, and anthelmintic effects. Such innovations are critical in enhancing treatment options in the medical field.

Career Highlights

Marc Montavon works at Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work has focused on creating compounds that not only advance medical science but also improve patient outcomes. His expertise and contributions are well recognized as he continues to push the boundaries of pharmaceutical research.

Collaborations

During his career, Montavon has collaborated with notable coworkers, including Roland Reiner and Erika Bohni. These partnerships exemplify the collaborative spirit of innovation, where combined expertise leads to groundbreaking developments in healthcare.

Conclusion

Marc Montavon's inventive spirit and dedication to his field have resulted in significant advancements that benefit both the pharmaceutical industry and society at large. His research and patent contributions pave the way for future innovations, highlighting the importance of continuing research and development in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…